Mounjaro vs. Rybelsus
Mounjaro and Rybelsus offer contrasting approaches to treating type 2 diabetes. Mounjaro is a dual GIP and GLP-1 agonist administered via injection, delivering superior HbA1c reductions and moderate weight loss. Rybelsus, an oral GLP-1 agonist, achieves less pronounced glucose control and weight effects. Both are used off-label for weight management. Side effects like nausea are common, though Rybelsus may cause additional gastrointestinal discomfort. Mounjaro’s cost is significantly higher at $1,135/month compared to Rybelsus’s $875/month. Neither drug faces shortages.
Enhances the effects of both incretin hormones. GIP improves insulin sensitivity and enhances fat metabolism, while GLP-1 reduces appetite, delays gastric emptying, and promotes insulin secretion, making it effective for blood sugar control and weight loss.
Common Side Effects
Nausea, vomiting, diarrhea, decreased appetite, and indigestion
Serious Potential Side Effects
Pancreatitis, thyroid tumors (potential risk), gallbladder issues, kidney problems, and serious allergic reactions
Slows gastric emptying, reduces appetite, and enhances feelings of fullness, leading to lower calorie intake. It also stimulates insulin release and reduces glucagon secretion, improving blood sugar control.
Common Side Effects
Nausea, diarrhea, vomiting, and abdominal pain.
Serious Potential Side Effects
Pancreatitis, thyroid tumors (potential risk), gallbladder issues, kidney problems, and serious allergic reactions